Your browser doesn't support javascript.
loading
Oral and inhaled corticosteroid dose reductions with tezepelumab versus placebo in patients with severe, uncontrolled asthma from DESTINATION.
Wechsler, Michael E; Stolz, Daiana; Lugogo, Njira L; Caveney, Scott; Almqvist, Gun; Bednarczyk, Artur; Kotalik, Ales; Chandarana, Shradha; Ambrose, Christopher S.
Afiliação
  • Wechsler ME; Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colo. Electronic address: mikewechsler@gmail.com.
  • Stolz D; University Medical Center Freiburg, Clinic of Pneumology, Department of Medicine, University of Freiburg, Freiburg, Germany.
  • Lugogo NL; Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Mich.
  • Caveney S; Global Development, Inflammation, R&D, Amgen, Thousand Oaks, Calif.
  • Almqvist G; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Bednarczyk A; Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Warsaw, Poland.
  • Kotalik A; Biometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Md.
  • Chandarana S; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
  • Ambrose CS; Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Md.
J Allergy Clin Immunol Pract ; 2024 Aug 08.
Article em En | MEDLINE | ID: mdl-39127103
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article